TITLE

The FDA's wake-up call to insomniacs

AUTHOR(S)
Podolsky, D.; Sherrid, P.
PUB. DATE
June 1992
SOURCE
U.S. News & World Report;6/1/92, Vol. 112 Issue 21, p71
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that Halcion, the sleeping pill banned in Britain because of concerns over psychiatric side effects, should stay on the market in the United States but with clearer, bolder warnings, an advisory panel of the Food and Drug Administration (FDA) concluded last week. Low doses of the drug; Drug makers sell many alternatives to Halcion; Side effects.
ACCESSION #
9206013443

 

Related Articles

  • Quick drug approval. Spencer, P.L. // Consumers' Research Magazine;Jan1992, Vol. 75 Issue 1, p6 

    Reports briefly on several significant events for consumers in Washington. Food and Drug Administration (FDA) plans to get prescription drug approval-process to market sooner; Department of Transportation wants to allow airports to charge airlines higher fees for landing during congested hours;...

  • Good news for Tar Heel pharmacists.  // Drug Topics;8/2/93, Vol. 137 Issue 15, p6 

    Reports on the passage of two bills supported by North Carolina pharmacists. Right of consumers to select pharmacy of their choice; Registration with the state board of pharmacy of mail-order pharmacies that distribute drugs to residents in the state.

  • Untitled. Conlan, Michael F. // Drug Topics;8/2/93, Vol. 137 Issue 15, p80 

    Reports on the development in the pharmaceutical industry. DEA's lobby in Congress for power to tighten regulations over Schedule III Controlled Substance drugs; Federal government's methodical five-year probe of the generic drug industry; Deadline of application for new Medicare supplier...

  • What to do when things go wrong.  // Environmental Nutrition;Oct96, Vol. 19 Issue 10, p3 

    Reports that the MEDWatch program of the Food and Drug Administration gives assistance to consumers who experience adverse effects from medications. Possible product recalls after analysis of situation; Contact information.

  • Speeding help and hope to the desperately ill. Young, F.E. // FDA Consumer;Feb1989, Vol. 23 Issue 1, p8 

    Explains the US Food and Drug Administration's (FDA) most recent steps to reduce the time needed to test new drugs for life-threatening diseases, (such as acquired immune deficiency syndrome and cancer), and diseases that cause permanent disability. Ensuring proper safeguards for safety and...

  • Putting pressure on illegal steroid traffic. Modeland, V. // FDA Consumer;Oct89, Vol. 23 Issue 8, p33 

    Reports on recent US law enforcement agency investigation, indictments and prosecutions under the Anti-Drug Abuse Act of 1988. This Act prohibits distribution of anabolic steroids, a synthetic derivative of testosterone, for any use other than treatment of a disease under a physician's orders.

  • Speedier approval rules.  // FDA Consumer;Mar1993, Vol. 27 Issue 2, p5 

    Reports that final rules to speed the approval of drugs and biologics for people with serious or life-threatening diseases, such as cancer, AIDS, or Alzheimer's disease, went into effect on Jan. 11, 1993. Regulations published in the Dec. 11, 1992 issue of the `Federal Register'; Benefits of...

  • U.S. drug policy: Addicted to failure. Falco, Mathea // Foreign Policy;Spring96, Issue 102, p120 

    Focuses on the drug policy of the United States. Antidrug programs of the United States; Political appeal of the supply-side approach to drugs; Blaming on foreigners for America's recurring drug epidemics; Concentration on domestic demand of drugs; Need to develop a new drug policy.

  • Pharmaceutical spending and German reunification: Parity comes quickly to Berlin. Katz, Eric M. // Health Care Financing Review;Spring94, Vol. 15 Issue 3, p141 

    Examines drug outlays by the statutory sickness funds during the first two years of unified operations in Germany. Insurance structure; Pharmaceutical benefits and spending; Pharmaceuticals and reunification; Transition in pricing; Transition in copayments; Transition in market supply;...

  • What's the price? Brookman, Faye // Drug Topics;9/5/94, Vol. 138 Issue 17, p92 

    Reports on the charges filed against major drug store chains in Connecticut for violating the mandatory use of price tags. Elimination of labor cost from item pricing by using scanning; Chains cited; Civil penalties for the violation.

Share

Read the Article

Other Topics